Ravi Salgia - Publications

Affiliations: 
Cancer Biology University of Chicago, Chicago, IL 
Area:
Oncology, Molecular Biology

416 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, ... ... Salgia R, et al. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers. 13. PMID 34204917 DOI: 10.3390/cancers13112776  1
2021 Singhal SS, Srivastava S, Mirzapoiazova T, Horne D, Awasthi S, Salgia R. Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Letters. PMID 34126193 DOI: 10.1016/j.canlet.2021.06.004  0.01
2021 Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, ... ... Salgia R, et al. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British Journal of Cancer. PMID 34088988 DOI: 10.1038/s41416-021-01441-7  1
2021 Erhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, ... ... Salgia R, et al. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34088750 DOI: 10.1158/1055-9965.EPI-20-1555  1
2021 Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers. 13. PMID 34071259 DOI: 10.3390/cancers13112653  1
2021 Khan P, Ebenezer NS, Siddiqui JA, Maurya SK, Lakshmanan I, Salgia R, Batra SK, Nasser MW. MicroRNA-1: Diverse role of a small player in multiple cancers. Seminars in Cell & Developmental Biology. PMID 34034986 DOI: 10.1016/j.semcdb.2021.05.020  1
2021 Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, et al. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nature Communications. 12: 3039. PMID 34031395 DOI: 10.1038/s41467-021-23171-3  0.01
2021 Soldi R, Ghosh Halder T, Sampson S, Vankayalapati H, Weston A, Thode T, Bhalla Md K, Ng S, Rodriguez Del Villar R, Drenner K, Kaadige MR, Horrigan SK, Batra S, Salgia R, Sharma S. . The Journal of Pharmacology and Experimental Therapeutics. PMID 34006586 DOI: 10.1124/jpet.121.000634  0.01
2021 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R. Utility of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients with Non-small Cell Lung Cancer. Chest. PMID 33878340 DOI: 10.1016/j.chest.2021.04.016  0.01
2021 Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, ... ... Salgia R, et al. Germline mutations and age at onset of lung adenocarcinoma. Cancer. PMID 33858029 DOI: 10.1002/cncr.33573  0.01
2021 Lakshmanan I, Chaudhary S, Vengoji R, Seshacharyulu P, Rachagani S, Carmicheal J, Jahan R, Atri P, Venkata Ramakanth C, Gupta R, Marimuthu S, Perumal N, Rauth S, Kaur S, Mallya K, ... ... Salgia R, et al. ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Molecular Oncology. PMID 33792183 DOI: 10.1002/1878-0261.12956  1
2021 Chen BT, Jin T, Ye N, Mambetsariev I, Wang T, Wong CW, Chen Z, Rockne RC, Colen RR, Holodny AI, Sampath S, Salgia R. Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. Frontiers in Oncology. 11: 621088. PMID 33747933 DOI: 10.3389/fonc.2021.621088  0.01
2021 Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW. RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer. 20: 54. PMID 33740988 DOI: 10.1186/s12943-021-01338-2  1
2021 Chau B, Ituarte PH, Shinde A, Li R, Vazquez J, Glaser S, Massarelli E, Salgia R, Erhunmwunsee L, Ashing K, Amini A. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Medicine. PMID 33734614 DOI: 10.1002/cam4.3848  0.01
2021 Liu J, Hui C, Ladbury C, Waddington T, Erhunmwunsee L, Raz D, Kim J, Salgia R, Chenery S, Pearlstein D, Schwer A, Amini A. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clinical Lung Cancer. PMID 33712362 DOI: 10.1016/j.cllc.2021.01.003  0.01
2021 Salgia R, Boehmer LM, Celestin C, Yu H, Spigel DR. Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. Jco Oncology Practice. OP2000899. PMID 33689449 DOI: 10.1200/OP.20.00899  0.01
2021 Salgia R, Kulkarni P, Levine H, Loughlin DT. Quantifying Cancer: More Than Just a Numbers Game. Trends in Cancer. PMID 33648875 DOI: 10.1016/j.trecan.2021.02.002  1
2021 Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R. Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clinical Lung Cancer. PMID 33640299 DOI: 10.1016/j.cllc.2021.01.009  0.01
2021 Singhal SS, Mohanty A, Kulkarni P, Horne D, Awasthi S, Salgia R. RLIP Depletion Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells. Carcinogenesis. PMID 33623991 DOI: 10.1093/carcin/bgab016  1
2021 Bhattacharya S, Mohanty A, Achuthan S, Kotnala S, Jolly MK, Kulkarni P, Salgia R. Group Behavior and Emergence of Cancer Drug Resistance. Trends in Cancer. PMID 33622644 DOI: 10.1016/j.trecan.2021.01.009  1
2021 Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, et al. Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33588109 DOI: 10.1016/j.jtho.2021.01.1628  0.01
2021 Singhal J, Kulkarni P, Horne D, Awasthi S, Salgia R, Singhal SS. Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Molecular Carcinogenesis. PMID 33544936 DOI: 10.1002/mc.23285  1
2021 Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports. Medicine. 2: 100186. PMID 33521700 DOI: 10.1016/j.xcrm.2020.100186  1
2021 Singhal SS, Horne D, Singhal J, Awasthi S, Salgia R. Activating p53 function by targeting RLIP. Biochimica Et Biophysica Acta. Reviews On Cancer. 188512. PMID 33460725 DOI: 10.1016/j.bbcan.2021.188512  0.01
2021 Bosserman LD, Cianfrocca M, Yuh B, Yeon C, Chen H, Sentovich S, Polverini A, Zachariah F, Deaville D, Lee AB, Sedrak MS, King E, Gray S, Morse D, Glaser S, ... ... Salgia R, et al. Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. Journal of Clinical Medicine. 10. PMID 33430334 DOI: 10.3390/jcm10020188  1
2020 Ando K, Ozonoff A, Lee SY, Voisine M, Parker JT, Nakanishi R, Nishimura S, Yang J, Grace Z, Tran B, Diefenbach TJ, Maehara Y, Yasui H, Irino T, Salgia R, et al. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clinical Colorectal Cancer. PMID 33731288 DOI: 10.1016/j.clcc.2020.11.005  1
2020 Reckamp KL, McQuerry JA, Mambetsariev I, Pharaon R, Yost SE, Fricke J, Mirzapoiazova T, Pillai RK, Khan Z, Fakih M, Yuan Y, Koczywas M, Massarelli E, Kulkarni P, Pal SK, ... ... Salgia R, et al. Co-stimulatory and co-inhibitory immune markers in solid tumors with alterations. Future Science Oa. 7: FSO662. PMID 33437521 DOI: 10.2144/fsoa-2020-0159  1
2020 Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers. 12. PMID 33419311 DOI: 10.3390/cancers12123851  0.01
2020 Lapidot M, Case AE, Larios D, Gandler HI, Meng C, Tošić I, Weisberg EL, Poitras MJ, Gokhale PC, Paweletz CP, Podar K, Salgia R, Saladi SV, Griffin JD, Frank DA, et al. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers. 13. PMID 33374980 DOI: 10.3390/cancers13010007  1
2020 Ebelt ND, Zuniga E, Marzagalli M, Zamloot V, Blazar BR, Salgia R, Manuel ER. -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines. 8. PMID 33339195 DOI: 10.3390/biomedicines8120617  0.01
2020 Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring exon 14 mutation: a research report. Cold Spring Harbor Molecular Case Studies. 6. PMID 33335011 DOI: 10.1101/mcs.a005785  0.01
2020 Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, Salgia R, Batra SK, Nasser MW. Epigenetic Landscape of Small Cell Lung Cancer: Small Image of a Giant Recalcitrant Disease. Seminars in Cancer Biology. PMID 33220460 DOI: 10.1016/j.semcancer.2020.11.006  1
2020 Srivastava S, Pang KM, Iida M, Nelson MS, Liu J, Nam A, Wang J, Mambetsariev I, Pillai R, Mohanty A, McDaniel N, Behal A, Kulkarni P, Wheeler DL, Salgia R. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. Iscience. 23: 101692. PMID 33196021 DOI: 10.1016/j.isci.2020.101692  1
2020 Fricke J, Mambetsariev I, Pharaon R, Subbiah S, Rajurkar S, Salgia R. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report. Medicine. 99: e22323. PMID 33181636 DOI: 10.1097/MD.0000000000022323  0.01
2020 Pharaon R, Mambetsariev I, Fricke J, Salgia R. Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease. 12: 5096-5103. PMID 33145086 DOI: 10.21037/jtd.2019.08.14  0.01
2020 Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. Journal of Thoracic Disease. 12: 5086-5095. PMID 33145085 DOI: 10.21037/Jtd.2020.04.18  0.01
2020 Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Arvanitis LD, Nasser MW, Batra SK, Orban J, ... ... Salgia R, et al. Erratum: A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. Iscience. 23: 101679. PMID 33134900 DOI: 10.1016/j.isci.2020.101679  1
2020 Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, Sedrak M, Massarelli E, Welsh JW, Amini A. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clinical Lung Cancer. PMID 33039348 DOI: 10.1016/J.Cllc.2020.09.004  0.01
2020 Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Nasser MW, Batra SK, Orban J, Jolly MK, ... ... Salgia R, et al. A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. Iscience. 23: 101496. PMID 32947124 DOI: 10.1016/J.Isci.2020.101496  1
2020 Salgia R, Kulkarni P. Integrating Clinical and Translational Research Networks-Building Team Medicine. Journal of Clinical Medicine. 9. PMID 32942638 DOI: 10.3390/Jcm9092975  1
2020 Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R. Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine. 9. PMID 32751469 DOI: 10.3390/Jcm9082433  1
2020 Huang LS, Kotha SR, Avasarala S, VanScoyk M, Winn RA, Pennathur A, Yashaswini PS, Bandela M, Salgia R, Tyurina YY, Kagan VE, Zhu X, Reddy SP, Sudhadevi T, Punathil-Kannan PK, et al. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. The Journal of Biological Chemistry. PMID 32732285 DOI: 10.1074/Jbc.Ra120.012680  1
2020 Amanam I, Mambetsariev I, Gupta R, Salgia R. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? Jco Oncology Practice. JOP1900701. PMID 32644904 DOI: 10.1200/JOP.19.00701  0.01
2020 Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Hozo I, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. Jco Oncology Practice. OP2000117. PMID 32639928 DOI: 10.1200/Op.20.00117  0.01
2020 Malik R, Mambetsariev I, Fricke J, Chawla N, Nam A, Pharaon R, Salgia R. MET receptor in oncology: From biomarker to therapeutic target. Advances in Cancer Research. 147: 259-301. PMID 32593403 DOI: 10.1016/Bs.Acr.2020.04.006  0.01
2020 Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, Baroz A, Fricke J, Pharaon R, Romo H, Waddington T, Babikian R, Buck L, Kulkarni P, Cianfrocca M, et al. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. Journal of Clinical Medicine. 9. PMID 32560187 DOI: 10.3390/Jcm9061884  1
2020 Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee PP, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer (Amsterdam, Netherlands). 146: 174-181. PMID 32554069 DOI: 10.1016/J.Lungcan.2020.05.025  1
2020 Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine. 9. PMID 32549358 DOI: 10.3390/Jcm9061870  1
2020 Presant CA, Salgia R, Kulkarni P, Tiep BL, Sanani S, Leach B, Ashing K, Sandoval J, Sedrak MS, Landau S, Yeung S, Raz D, Subbiah S. Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. Journal of Clinical Medicine. 9. PMID 32545244 DOI: 10.3390/Jcm9061820  1
2020 Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, ... ... Salgia R, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. PMID 32531268 DOI: 10.1016/J.Ccell.2020.04.017  1
2020 Galvez C, Jacob S, Finkelman BS, Zhao J, Tegtmeyer K, Chae YK, Mohindra N, Salgia R, Jovanovic B, Behdad A, Villaflor V. The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget. 11: 1953-1960. PMID 32523650 DOI: 10.18632/Oncotarget.27602  1
2020 McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, ... Salgia R, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32439698 DOI: 10.1158/1078-0432.Ccr-19-3142  1
2020 Singhal J, Chikara S, Horne D, Awasthi S, Salgia R, Singhal SS. Targeting RLIP with CRISPR/Cas9 controls tumor growth. Carcinogenesis. PMID 32426802 DOI: 10.1093/Carcin/Bgaa048  0.01
2020 Jana S, Krishna M, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Therapeutic targeting of miRNA-216b in cancer. Cancer Letters. 484: 16-28. PMID 32387443 DOI: 10.1016/J.Canlet.2020.04.020  0.01
2020 Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treatment Reviews. 87: 102022. PMID 32334240 DOI: 10.1016/J.Ctrv.2020.102022  1
2020 Mirzapoiazova T, Pozhitkov A, Nam A, Mambetsariev I, Nelson MS, Tan YC, Zhang K, Raz D, Singhal S, Nasser MW, Kulkarni P, Batra SK, Sattler M, Salgia R. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. International Journal of Oncology. PMID 32236606 DOI: 10.3892/Ijo.2020.5034  1
2020 Chen BT, Jin T, Ye N, Mambetsariev I, Daniel E, Wang T, Wong CW, Rockne RC, Colen R, Holodny AI, Sampath S, Salgia R. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magnetic Resonance Imaging. PMID 32179095 DOI: 10.1016/J.Mri.2020.03.002  0.01
2020 Strickler JH, LoRusso PM, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly EB, Afar DEH, Naumovski L, Ramanathan RK. Phase 1 Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients With Advanced Solid Tumors. Molecular Cancer Therapeutics. PMID 32127466 DOI: 10.1158/1535-7163.Mct-19-0529  1
2020 Krishna BM, Jana S, Panda AK, Horne D, Awasthi S, Salgia R, Singhal SS. Association of Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies †. Cancers. 12. PMID 32085560 DOI: 10.3390/Cancers12020471  0.01
2020 Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, ... ... Salgia R, et al. Precision medicine and actionable alterations in lung cancer: A single institution experience. Plos One. 15: e0228188. PMID 32045431 DOI: 10.1371/Journal.Pone.0228188  1
2020 Jana S, Krishna BM, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. SOX9: The Master Regulator of Cell Fate in Breast Cancer. Biochemical Pharmacology. 113789. PMID 31911091 DOI: 10.1016/J.Bcp.2019.113789  0.01
2020 Carmicheal J, Atri P, Sharma S, Kumar S, Chirravuri Venkata R, Kulkarni P, Salgia R, Ghersi D, Kaur S, Batra SK. Presence and structure-activity relationship of intrinsically disordered regions across mucins. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 31908009 DOI: 10.1096/Fj.201901898Rr  1
2020 Singhal SS, Salgia R, Verma N, Horne D, Awasthi S. RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochimica Et Biophysica Acta. Reviews On Cancer. 1873: 188337. PMID 31904398 DOI: 10.1016/J.Bbcan.2020.188337  0.01
2020 Erhunmwunsee L, Hu H, Raquel C, Lopez LN, Shen J, Wong L, Kim JY, Raz DJ, Reckamp KL, Salgia R, Gray SW. Abstract PR08: Neighborhood-level social determinants impact non-small cell lung cancer aggressive somatic phenotypes Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-Pr08  0.01
2020 Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee P, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Abstract 3300: Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors Immunology. 80: 3300-3300. DOI: 10.1158/1538-7445.Am2020-3300  1
2020 Mohanty A, Nam A, Pozhitkov A, Yang L, Nelson M, Wu X, Kulkarni P, Massarelli E, Salgia R. Abstract 2607: Integrin Beta4/Paxillin mediated chemoresistance in lung adenocarcinoma Cancer Research. 80: 2607-2607. DOI: 10.1158/1538-7445.Am2020-2607  1
2020 Amini A, Chau B, Mambetsariev I, Huntzinger C, Shirvani S, Reckamp K, Massarelli E, Wong J, Salgia R. Expanding the Definition of Oligometastatic in Lung Adenocarcinoma International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.588  0.01
2020 Amini A, Chau B, Mambetsariev I, Huntzinger C, Shirvani S, Koczywas M, Reckamp K, Massarelli E, Wong J, Salgia R. Prognostic Impact of Malignant Pleural Effusion in Patients with Oligometastatic Lung Adenocarcinoma International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.586  0.01
2019 Griffiths JI, Cohen AL, Jones V, Salgia R, Chang JT, Bild AH. Opportunities for improving cancer treatment using systems biology. Current Opinion in Systems Biology. 17: 41-50. PMID 32518857 DOI: 10.1016/J.Coisb.2019.10.018  0.01
2019 Zhang K, Yang L, Wang J, Sun T, Guo Y, Nelson R, Tong TR, Pangeni R, Salgia R, Raz DJ. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Communication and Signaling : Ccs. 17: 167. PMID 31842906 DOI: 10.1186/S12964-019-0480-X  0.01
2019 Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncology (London, England). PMID 31778074 DOI: 10.2217/Fon-2019-0653  1
2019 Nardi IK, Stark JM, Larsen A, Salgia R, Raz DJ. USP22 interacts with PALB2 and promotes chemotherapy resistance via homologous recombination of DNA double strand breaks. Molecular Cancer Research : McR. PMID 31685642 DOI: 10.1158/1541-7786.Mcr-19-0053  0.01
2019 Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, ... ... Salgia R, et al. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine. 8. PMID 31635338 DOI: 10.3390/Jcm8101726  1
2019 Mirzapoiazova T, Li H, Nathan A, Srivstava S, Nasser MW, Lennon F, Armstrong B, Mambetsariev I, Chu PG, Achuthan S, Batra SK, Kulkarni P, Salgia R. Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. Journal of Clinical Medicine. 8. PMID 31635288 DOI: 10.3390/Jcm8101723  1
2019 Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, ... Salgia R, et al. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 8: 49. PMID 31484920 DOI: 10.1038/s41389-019-0159-6  1
2019 Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, ... ... Salgia R, et al. Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31470129 DOI: 10.1016/J.Jtho.2019.08.012  1
2019 Roth KG, Mambetsariev I, Kulkarni P, Salgia R. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine. PMID 31327706 DOI: 10.1016/J.Molmed.2019.06.009  1
2019 Krishna BM, Jana S, Singhal J, Horne D, Awasthi S, Salgia R, Singhal SS. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Letters. 461: 123-131. PMID 31326555 DOI: 10.1016/J.Canlet.2019.07.012  0.01
2019 Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R. Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. Journal of Clinical Medicine. 8. PMID 31315252 DOI: 10.3390/Jcm8071038  1
2019 Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. Journal of Clinical Pharmacology. PMID 31274208 DOI: 10.1002/Jcph.1476  0.01
2019 Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, ... ... Salgia R, et al. Pathologic considerations and standardization in mesothelioma clinical trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31260832 DOI: 10.1016/J.Jtho.2019.06.020  0.01
2019 Hill A, Gupta R, Zhao D, Vankina R, Amanam I, Salgia R. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research. 178: 3-43. PMID 31209840 DOI: 10.1007/978-3-030-16391-4_1  0.01
2019 Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer (Amsterdam, Netherlands). 133: 136-143. PMID 31200820 DOI: 10.1016/J.Lungcan.2019.05.020  0.01
2019 Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S. Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Molecular Carcinogenesis. PMID 31006917 DOI: 10.1002/Mc.23026  0.01
2019 Wang C, Kulkarni P, Salgia R. Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy Oncolytics. 13: 1-6. PMID 30976658 DOI: 10.1016/J.Omto.2019.02.001  1
2019 Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncologica (Stockholm, Sweden). 1-7. PMID 30958075 DOI: 10.1080/0284186X.2019.1599138  0.01
2019 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868. PMID 30936412 DOI: 10.1158/1535-7163.MCT-18-1183  1
2019 Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clinical and Translational Medicine. 8: 9. PMID 30887236 DOI: 10.1186/S40169-019-0225-X  0.01
2019 Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Onuchic JN, Levine H, ... ... Salgia R, et al. Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. Biomolecules. 9. PMID 30813315 DOI: 10.3390/biom9020077  1
2019 Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S. RLIP: An existential requirement for breast carcinogenesis. Biochimica Et Biophysica Acta. Reviews On Cancer. 1871: 281-288. PMID 30771458 DOI: 10.1016/J.Bbcan.2019.02.001  0.01
2019 Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. American Journal of Clinical Oncology. PMID 30741758 DOI: 10.1097/Coc.0000000000000508  0.01
2019 Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. RLIP inhibition suppresses breast-to-lung metastasis. Cancer Letters. 447: 24-32. PMID 30684594 DOI: 10.1016/J.Canlet.2019.01.023  0.01
2019 Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R. The DNA Walk and its Demonstration of Deterministic Chaos- Relevance to Genomic Alterations in Lung Cancer. Bioinformatics (Oxford, England). PMID 30615123 DOI: 10.1093/Bioinformatics/Bty1021  1
2019 Chung V, Frankel P, Shibata S, Mambetsariev I, Yin H, Mirzapoiazova T, Mambetsariev B, Kulkarni P, Lim D, Li D, Chao J, Fakih M, Bild A, Pillai R, Adalsteinsson O, ... ... Salgia R, et al. Abstract B13: Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer Clinical Trials. 79. DOI: 10.1158/1538-7445.Panca19-B13  1
2019 Singhal SS, Chikara S, Singhal J, Horne D, Salgia R, Awasthi S. Abstract 4801: 2’-Hydroxyflavanone, a diet-derived citrus bioflavonoid, inhibitsin vitroandin vivogrowth of breast cancer cells by targeting RLIP Cancer Research. 79: 4801-4801. DOI: 10.1158/1538-7445.Am2019-4801  0.01
2019 Gautam SK, Kanchan R, Atri P, Siddiqui J, Rauth S, Mahapatra S, Jain M, Moorthy PP, Salgia R, Band V, Batra SK, Nasser MW. Abstract 2017: Blocking ErbB-c-Met-FAK signaling axis suppresses brain metastasis of breast cancer Cancer Research. 79: 2017-2017. DOI: 10.1158/1538-7445.Am2019-2017  1
2019 McDaniel NK, Iida M, Nickel KP, Rodems TS, Swick AD, Prabakaran PJ, Eckers-Kubatzke JC, Welke NB, Kranjac C, Schulz AE, Kimple RJ, Salgia R, Wheeler DL. Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A128  1
2018 Mason C, Ellis PG, Lokay K, Barry A, Dickson N, Page R, Polite B, Salgia R, Savin M, Shamah C, Socinski MA. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways : the Foundation of Value-Based Care. 4: 49-54. PMID 31453358 DOI: 10.25270/jcp.2018.02.00001  0.01
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.Ccr-18-3194  1
2018 Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, ... Salgia R, et al. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biology & Therapy. 1-10. PMID 30311833 DOI: 10.1080/15384047.2018.1472193  1
2018 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine. 7: 32. PMID 30294755 DOI: 10.1186/S40169-018-0210-9  0.01
2018 Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology. PMID 30286944 DOI: 10.1053/J.Seminoncol.2018.06.002  0.01
2018 Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers M, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, ... ... Salgia R, et al. Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30266660 DOI: 10.1016/J.Jtho.2018.08.2036  1
2018 Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. Journal of Proteomics. PMID 30248461 DOI: 10.1016/J.Jprot.2018.09.005  0.01
2018 Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS. Metastasis of Breast Tumor Cells to Brain is suppressed by Targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Letters. PMID 30223070 DOI: 10.1016/J.Canlet.2018.09.015  0.01
2018 Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Molecular Carcinogenesis. PMID 30136444 DOI: 10.1002/Mc.22894  0.01
2018 Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. Journal of Oncology Practice. JOP1800127. PMID 30044685 DOI: 10.1200/Jop.18.00127  0.01
2018 Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Heuristic value-based framework for lung cancer decision-making. Oncotarget. 9: 29877-29891. PMID 30042820 DOI: 10.18632/Oncotarget.25643  1
2018 Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 29948021 DOI: 10.1200/Jco.2017.35.15_Suppl.Tps11628  1
2018 Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P. Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine. 7. PMID 29914187 DOI: 10.3390/Jcm7060156  1
2018 Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M. Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget. 9: 26226-26242. PMID 29899855 DOI: 10.18632/Oncotarget.25360  1
2018 Gong J, Salgia R. Managing Patients With Relapsed Small-Cell Lung Cancer. Journal of Oncology Practice. 14: 359-366. PMID 29894664 DOI: 10.1200/Jop.18.00204  0.01
2018 Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 9: 19793-19806. PMID 29731983 DOI: 10.18632/Oncotarget.24857  1
2018 Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treatment Reviews. 66: 95-103. PMID 29730462 DOI: 10.1016/J.Ctrv.2018.04.008  0.01
2018 Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS. 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget. 9: 18053-18068. PMID 29719590 DOI: 10.18632/Oncotarget.24720  0.01
2018 Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. European Urology. PMID 29685646 DOI: 10.1016/J.Eururo.2018.03.032  0.01
2018 Gong J, Pan K, Fakih M, Pal S, Salgia R. Value-based genomics. Oncotarget. 9: 15792-15815. PMID 29644010 DOI: 10.18632/Oncotarget.24353  0.01
2018 Mambetsariev I, Vora L, Yu KW, Salgia R. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. Bmc Cancer. 18: 314. PMID 29562902 DOI: 10.1186/S12885-018-4222-Z  0.01
2018 Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, et al. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. PMID 29551267 DOI: 10.1016/J.Cell.2018.02.048  1
2018 Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology, Biology, Physics. PMID 29487024 DOI: 10.1016/J.Ijrobp.2018.01.046  1
2018 Salgia R, Kulkarni P. The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends in Cancer. 4: 110-118. PMID 29458961 DOI: 10.1016/J.Trecan.2018.01.001  1
2018 Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncology (London, England). PMID 29451020 DOI: 10.2217/Fon-2017-0545  0.01
2018 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper Aerodigestive malignancies. Biochimica Et Biophysica Acta. PMID 29369779 DOI: 10.1016/J.Bbcan.2018.01.003  1
2018 Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal For Immunotherapy of Cancer. 6: 8. PMID 29357948 DOI: 10.1186/S40425-018-0316-Z  0.01
2018 Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. Cancer Biology & Therapy. 0. PMID 29303405 DOI: 10.1080/15384047.2017.1416937  1
2018 McHenry AJ, Sondarva G, Ananthanarayanan V, Hess A, Simms PE, Alsayed A, Kataoka H, Marusarz J, Kumar S, Salgia R, Dudek A, Borowicz S, Rana A. Abstract 5514: Loss of hepatocyte growth factor activator inhibitor type-1 (HAI-1) in human lung adenocarcinomas promotes RON receptor phosphorylation and increased sensitivity to crizotinib Cancer Research. 78: 5514-5514. DOI: 10.1158/1538-7445.Am2018-5514  0.01
2017 Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. 8: 71223-71233. PMID 29050358 DOI: 10.18632/Oncotarget.19333  1
2017 Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 8: 67639-67650. PMID 28978059 DOI: 10.18632/Oncotarget.18797  1
2017 Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 8: 62817. PMID 28977992 DOI: 10.18632/Oncotarget.20632  0.01
2017 Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, et al. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. Bmc Cancer. 17: 646. PMID 28899363 DOI: 10.1186/S12885-017-3641-6  0.01
2017 Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Scientific Reports. 7: 9192. PMID 28835699 DOI: 10.1038/S41598-017-09078-4  1
2017 Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. PMID 28746911 DOI: 10.18632/oncotarget.19333  1
2017 Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society. 29: 125-134. PMID 28720259 DOI: 10.1016/J.Ejon.2017.06.003  0.01
2017 Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. PMID 28711923 DOI: 10.18632/oncotarget.18797  1
2017 Wood K, Byron E, Janisch L, Salgia R, Sharma MR. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. American Journal of Clinical Oncology. PMID 28654574 DOI: 10.1097/Coc.0000000000000400  1
2017 Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. PMID 28628114 DOI: 10.1038/onc.2017.203  1
2017 Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncology Letters. 13: 4027-4034. PMID 28588695 DOI: 10.3892/Ol.2017.5956  1
2017 Brooks GA, Bosserman LD, Mambetsariev I, Salgia R. Value-Based Medicine and Integration of Tumor Biology. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 37: 833-840. PMID 28561700 DOI: 10.14694/EDBK_175519  0.01
2017 Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, Salgia R, Raz DJ. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. International Journal of Cancer. PMID 28481029 DOI: 10.1002/Ijc.30769  0.01
2017 Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews. 55: 181-189. PMID 28427013 DOI: 10.1016/J.Ctrv.2017.03.006  0.01
2017 Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget. PMID 28415827 DOI: 10.18632/Oncotarget.16376  1
2017 Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Molecular Cancer Therapeutics. 16: 555-565. PMID 28373408 DOI: 10.1158/1535-7163.Mct-16-0472  0.01
2017 Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. PMID 28368404 DOI: 10.1038/onc.2017.77  1
2017 Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, et al. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Investigational New Drugs. PMID 28299514 DOI: 10.1007/S10637-017-0446-Z  0.01
2017 Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 105: 7-13. PMID 28236984 DOI: 10.1016/J.Lungcan.2016.12.020  0.01
2017 Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. Oncotarget. PMID 28178681 DOI: 10.18632/Oncotarget.15030  0.01
2017 Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Science. PMID 28075524 DOI: 10.1111/Cas.13160  0.01
2017 Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. PMID 28061482 DOI: 10.18632/Oncotarget.14476  0.01
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10. PMID 28049763 DOI: 10.1126/Scisignal.Aag1064  1
2017 Zhang K, Tong TR, Yun X, Nelson R, Isaac N, Salgia R, Raz D. Abstract 4451: Elevated USP22 is a potential therapeutic target for human non-small cell lung cancer Cancer Research. 77: 4451-4451. DOI: 10.1158/1538-7445.Am2017-4451  0.01
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor Cancer Research. 77: 3333-3333. DOI: 10.1158/1538-7445.Am2017-3333  1
2016 Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet. Oncology. PMID 27836716 DOI: 10.1016/S1470-2045(16)30392-8  1
2016 Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Scientific Reports. 6: 32992. PMID 27623107 DOI: 10.1038/Srep32992  1
2016 Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. PMID 27602770 DOI: 10.18632/Oncotarget.11801  0.01
2016 Sattler M, Salgia R. MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: 1381-3. PMID 27565402 DOI: 10.1016/J.Jtho.2016.07.003  1
2016 Won B, Mambetsariev I, Salgia R. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. Bmc Cancer. 16: 568. PMID 27480287 DOI: 10.1186/S12885-016-2636-Z  0.01
2016 Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters. PMID 27450722 DOI: 10.1016/J.Canlet.2016.07.021  1
2016 Wood K, Hensing T, Salgia R. KRAS in Non-Small-Cell Lung Cancer-Reply. Jama Oncology. PMID 27442777 DOI: 10.1001/Jamaoncol.2016.2347  1
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  1
2016 Lovly CM, Salama AK, Salgia R. Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e585-93. PMID 27249771 DOI: 10.14694/EDBK_158808  1
2016 Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, ... ... Salgia R, et al. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. The Oncologist. PMID 27245569 DOI: 10.1634/Theoncologist.2015-0497  1
2016 Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. PMID 27244893 DOI: 10.18632/Oncotarget.9640  1
2016 Rosell R, Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Shaw AT, Narasimhan NI, Dorer DJ, Kerstein D, Camidge DR. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S114. PMID 27198273 DOI: 10.1016/S1556-0864(16)30245-3  1
2016 Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Review of Molecular Diagnostics. 16: 737-49. PMID 27139190 DOI: 10.1080/14737159.2016.1181545  0.01
2016 Wood K, Hensing T, Malik R, Salgia R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. Jama Oncology. PMID 27100819 DOI: 10.1001/Jamaoncol.2016.0405  1
2016 Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R. The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. CurēUs. 8: e533. PMID 27092293 DOI: 10.7759/Cureus.533  1
2016 Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Scientific Reports. 6: 24578. PMID 27080907 DOI: 10.1038/Srep24578  1
2016 Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. CurēUs. 8: e513. PMID 27026837 DOI: 10.7759/Cureus.513  0.01
2016 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. PMID 26980710 DOI: 10.18632/Oncotarget.8040  1
2016 Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, ... ... Salgia R, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. PMID 26934441 DOI: 10.18632/Oncotarget.7739  1
2016 Lukas RV, Kumthekar P, Rizvi S, Salgia R. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncology (London, England). 12: 1045-58. PMID 26888310 DOI: 10.2217/Fon.16.17  1
2016 Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. PMID 26871945 DOI: 10.18632/Oncotarget.7297  0.01
2016 Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, ... ... Salgia R, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/J.Jtho.2016.01.012  1
2016 Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee M, Lee S, ... ... Salgia R, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26802155 DOI: 10.1093/Annonc/Mdw008  1
2016 Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biology & Therapy. 17: 91-103. PMID 26574927 DOI: 10.1080/15384047.2015.1108495  1
2016 Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J, trial TCEct. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. Journal of Clinical Oncology. 34: 9069-9069. DOI: 10.1200/Jco.2016.34.15_Suppl.9069  0.01
2016 Shi P, Oh Y, Zhang G, Yao W, Yue P, Kanteti R, Riehm J, Salgia R, Owonikoko T, Ramalingam SS, Chen M, Sun S. Abstract 2105: c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors Cancer Research. 76: 2105-2105. DOI: 10.1158/1538-7445.Am2016-2105  1
2016 Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype Cancer Biology and Therapy. 17: 91-103. DOI: 10.1080/15384047.2015.1108495  1
2015 Fu P, Usatyuk PV, Jacobson J, Cress AE, Garcia JG, Salgia R, Natarajan V. Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function. Pulmonary Circulation. 5: 619-30. PMID 26697169 DOI: 10.1086/683693  1
2015 Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, ... ... Salgia R, et al. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527777 DOI: 10.1200/Jco.2015.62.8719  1
2015 Salgia R. MET as a drug target. Clinical Advances in Hematology & Oncology : H&O. 13: 351-3. PMID 26352889  0.01
2015 Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R. Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26282382 DOI: 10.1016/J.Nano.2015.07.014  1
2015 Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, Singleton PA. HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. Frontiers in Oncology. 5: 164. PMID 26258071 DOI: 10.3389/Fonc.2015.00164  1
2015 Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. The Journal of Biological Chemistry. 290: 21901-14. PMID 26205821 DOI: 10.1074/Jbc.M115.670976  1
2015 Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nature Reviews. Clinical Oncology. PMID 26169924 DOI: 10.1038/Nrclinonc.2015.108  1
2015 Lukas RV, Hasan Y, Nicholas MK, Salgia R. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 22: 1978-9. PMID 26159887 DOI: 10.1016/J.Jocn.2015.04.009  1
2015 Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed on Erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26106072 DOI: 10.1158/1078-0432.Ccr-14-3281  1
2015 Nocula-Lugowska M, Lugowski M, Salgia R, Kossiakoff AA. Engineering synthetic antibody inhibitors specific for LD2 or LD4 motifs of paxillin. Journal of Molecular Biology. PMID 26087144 DOI: 10.1016/J.Jmb.2015.06.004  1
2015 Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports. 5: 10641. PMID 26073592 DOI: 10.1038/Srep10641  1
2015 Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, ... ... Salgia R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1741-8. PMID 25997818 DOI: 10.1093/Annonc/Mdv220  1
2015 Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.Cd-15-0285  1
2015 Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 89: 43-9. PMID 25936471 DOI: 10.1016/J.Lungcan.2015.03.023  1
2015 Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L1025-38. PMID 25795725 DOI: 10.1152/Ajplung.00306.2014  1
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  1
2015 Salgia R. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncology (London, England). 11: 489-500. PMID 25675128 DOI: 10.2217/Fon.14.275  0.01
2015 Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opinion On Drug Safety. 14: 485-93. PMID 25659177 DOI: 10.1517/14740338.2015.1007040  1
2015 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/Jto.0000000000000405  1
2015 Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular Cancer Therapeutics. 14: 461-9. PMID 25504632 DOI: 10.1158/1535-7163.Mct-14-0431  1
2015 Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, ... ... Salgia R, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 870-81. PMID 25492084 DOI: 10.1158/1078-0432.Ccr-14-2481  1
2015 Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Diseases of the Esophagus : Official Journal of the International Society For Diseases of the Esophagus. 28: 772-81. PMID 25142531 DOI: 10.1111/Dote.12276  1
2015 Sargis RM, Salgia R. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. American Journal of Clinical Oncology. 38: 442-7. PMID 23934135 DOI: 10.1097/Coc.0B013E3182A46896  0.01
2015 Tan W, Wilner KD, Lanzalone S, Polli A, Zierhut ML, Nickens D, O'Byrne KJ, Blackhall FH, Shaw AT, Salgia R, Jaime JC, Kim D. Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct117  1
2015 Tan YC, Rolle C, Zhu L, Srivastava MK, Sharma S, Salgia R. Abstract 4361: Efficacy of MET inhibitors in NSCLC with CBL alterations Cancer Research. 75: 4361-4361. DOI: 10.1158/1538-7445.Am2015-4361  1
2015 Jen J, Lin LL, Chen HT, Liao SY, Lo FY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer Oncogene. DOI: 10.1038/onc.2015.296  1
2014 Spigel DR, Weaver RW, McCleod M, Hamid O, Stille JR, Polzer J, Roberson S, Salgia R. 1472PPHASE II STUDY OF CARBOPLATIN/ETOPOSIDE PLUS LY2510924, A CXCR4 PEPTIDE ANTAGONIST, VERSUS CARBOPLATIN/ETOPOSIDE IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv514. PMID 28172401 DOI: 10.1093/Annonc/Mdu355.10  0.01
2014 Shaw A, Ou SI, Bang Y, Camidge R, Solomon B, Salgia R, Riely GJ, Varella-Garcia M, Shapiro G, Costa D, Doebele R, Le LP, Zheng Z, Stephenson P, Shreeve SM, et al. 1299PCLINICAL ACTIVITY OF CRIZOTINIB IN ROS1-REARRANGED NON-SMALL CELL LUNG CANCER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv458. PMID 28172052 DOI: 10.1093/Annonc/Mdu349.78  1
2014 Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG, Camidge R. 1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv455. PMID 28172024 DOI: 10.1093/Annonc/Mdu349.71  0.01
2014 West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Reports in Clinical Pathology. 1: 151-154. PMID 25541622 DOI: 10.5430/Crcp.V1N2P151  1
2014 Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (Chur, Switzerland). 32: 202-6. PMID 25391996 DOI: 10.3109/08977194.2014.980904  1
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  1
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, ... Salgia R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293  1
2014 Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 371: 1963-71. PMID 25264305 DOI: 10.1056/Nejmoa1406766  1
2014 Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. Plos One. 9: e105919. PMID 25221930 DOI: 10.1371/Journal.Pone.0105919  1
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  1
2014 Smieliauskas F, MacMahon H, Salgia R, Shih YC. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. Journal of Medical Screening. 21: 207-15. PMID 25118160 DOI: 10.1177/0969141314548055  0.01
2014 Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. Cns Oncology. 3: 61-75. PMID 25054901 DOI: 10.2217/Cns.13.66  1
2014 Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. The Journal of Biological Chemistry. 289: 24043-58. PMID 25023279 DOI: 10.1074/Jbc.M114.554766  1
2014 Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2328-34. PMID 24958824 DOI: 10.1200/Jco.2014.55.2307  1
2014 Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. British Journal of Anaesthesia. 113: i103-8. PMID 24920011 DOI: 10.1093/Bja/Aeu165  1
2014 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 5: 1392-433. PMID 24722523 DOI: 10.18632/Oncotarget.1891  1
2014 Salgia R. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Medicine. 3: 681-92. PMID 24711160 DOI: 10.1002/Cam4.238  0.01
2014 Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. Plos One. 9: e91577. PMID 24662916 DOI: 10.1371/Journal.Pone.0091577  1
2014 Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opinion On Investigational Drugs. 23: 675-92. PMID 24654596 DOI: 10.1517/13543784.2014.899350  1
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  1
2014 Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambronero J, Wary KK, Bindokas V, Dudek SM, Salgia R, Garcia JG, Natarajan V. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. The Journal of Biological Chemistry. 289: 13476-91. PMID 24634221 DOI: 10.1074/Jbc.M113.527556  1
2014 Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. Bmc Cancer. 14: 185. PMID 24628993 DOI: 10.1186/1471-2407-14-185  1
2014 Gong J, Wang Z, Polejaeva I, Salgia R, Kao CM, Chen CT, Chen G, Chen L. Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. Plos One. 9: e90059. PMID 24594684 DOI: 10.1371/Journal.Pone.0090059  0.01
2014 Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1666-75. PMID 24493831 DOI: 10.1158/1078-0432.Ccr-13-2070  1
2014 Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. Bmc Cancer. 14: 5. PMID 24386952 DOI: 10.1186/1471-2407-14-5  1
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  1
2014 Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Research. 74: 884-95. PMID 24305878 DOI: 10.1158/0008-5472.Can-12-3583  1
2014 Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology. 799: 85-117. PMID 24292963 DOI: 10.1007/978-1-4614-8778-4_5  1
2014 Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Letters. 343: 14-23. PMID 24041868 DOI: 10.1016/J.Canlet.2013.09.010  1
2014 Hasina R, Kawada I, Arif Q, Mueller J, Husain AN, Vokes EE, Salgia R. Abstract LB-239: Inhibition of MET/RON in lung cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-239  1
2014 Brand TM, Iida M, Corrigan KL, Luthar N, Hornung M, Toulany M, Gill P, Salgia R, Wheeler DL. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-215  1
2013 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. Journal of Carcinogenesis. 12: 20. PMID 24319345 DOI: 10.4103/1477-3163.120632  1
2013 Salgia R, Sattler M. A new hope for precision medicine. Science Translational Medicine. 5: 208fs38. PMID 24154598 DOI: 10.1126/Scitranslmed.3007622  1
2013 Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. Journal of Surgical Oncology. 108: 327-33. PMID 23893423 DOI: 10.1002/Jso.23382  0.01
2013 Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, ... ... Salgia R, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. Plos One. 8: e67668. PMID 23844053 DOI: 10.1371/Journal.Pone.0067668  1
2013 Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. International Journal of Medical Sciences. 10: 988-94. PMID 23801885 DOI: 10.7150/Ijms.5944  1
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, ... ... Salgia R, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  1
2013 Lukas RV, Vigneswaran J, Salgia R. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 99: e73-6. PMID 23748834 DOI: 10.1700/1283.14212  1
2013 Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. Bmc Cancer. 13: 269. PMID 23721559 DOI: 10.1186/1471-2407-13-269  1
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  1
2013 Zhao Y, Zhao J, Mialki RK, Wei J, Spannhake EW, Salgia R, Natarajan V. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. American Journal of Physiology. Lung Cellular and Molecular Physiology. 305: L56-63. PMID 23624790 DOI: 10.1152/Ajplung.00417.2012  1
2013 Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e254-8. PMID 23610116 DOI: 10.1200/Jco.2012.46.4289  1
2013 Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? Journal of Carcinogenesis. 12: 7. PMID 23599689 DOI: 10.4103/1477-3163.109253  0.01
2013 Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3068-77. PMID 23553849 DOI: 10.1158/1078-0432.Ccr-12-3381  1
2013 Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opinion On Therapeutic Targets. 17: 481-3. PMID 23506058 DOI: 10.1517/14728222.2013.781585  0.01
2013 Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, et al. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49: 525-33. PMID 23490885 DOI: 10.1016/J.Oraloncology.2013.02.003  1
2013 Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1089-96. PMID 23401458 DOI: 10.1200/Jco.2012.43.9422  0.01
2013 Lukas RV, Rezania K, Malec M, Salgia R. Teaching Video NeuroImages: myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. Neurology. 80: e55. PMID 23359380 DOI: 10.1212/Wnl.0B013E31827F0Fa1  1
2013 Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. The Journal of Biological Chemistry. 288: 2191-200. PMID 23212923 DOI: 10.1074/Jbc.M112.404780  1
2013 Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, ... ... Salgia R, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research. 73: 184-94. PMID 23100466 DOI: 10.1158/0008-5472.Can-12-0915  1
2013 Lukas RV, Bernard JT, Malik R, Finch A, Salgia R. Optic Nerve Radiation Recall Associated With Prior Pemetrexed Journal of Neurology Research. 3: 155-158. DOI: 10.4021/Jnr.V3I5.252  1
2013 Hembrough TA, Liao W, Thyparambil S, Erickson HS, Carey G, Guiel T, Heaton RB, Krizman D, Wistuba II, Salgia R, Burrows J. Development and clinical validation of an adeno/squamous multiplexed diagnostic assay for NSCLC. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19057  0.01
2012 Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets and Therapy. 2012: 7-12. PMID 24791250 DOI: 10.2147/ITT.S32617  0.01
2012 Lukas RV, Nicholas MK, Villaflor V, Hoffman PC, Salgia R. Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. Journal of Neurology Research. 2: 1-9. PMID 23504695 DOI: 10.4021/Jnr85W  1
2012 Sadiq AA, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: S372-4. PMID 23160322 DOI: 10.1097/JTO.0b013e31826df03e  0.01
2012 Sharma S, Dubinett S, Salgia R. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. American Journal of Respiratory and Critical Care Medicine. 186: 940-1. PMID 23155211 DOI: 10.1164/Rccm.201209-1597Ed  0.01
2012 Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, ... ... Salgia R, et al. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. Bmj Open. 2. PMID 23103606 DOI: 10.1136/Bmjopen-2012-001620  1
2012 Mollberg NM, Parsad NM, Armato SG, Vigneswaran J, Kindler HL, Sensakovic WF, Salgia R, Silverstein JC, Vigneswaran WT. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. International Surgery. 97: 65-70. PMID 23102002 DOI: 10.9738/Cc66.1  1
2012 Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. Plos One. 7: e45330. PMID 23028939 DOI: 10.1371/Journal.Pone.0045330  1
2012 Morales La Madrid A, La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Targeted Oncology. 7: 199-210. PMID 22968692 DOI: 10.1007/S11523-012-0227-8  0.01
2012 Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3  1
2012 Mollberg NM, Vigneswaran Y, Kindler HL, Warnes C, Salgia R, Husain AN, Vigneswaran WT. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. The Annals of Thoracic Surgery. 94: 1086-92. PMID 22921241 DOI: 10.1016/J.Athoracsur.2012.05.102  1
2012 Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 856-65. PMID 22722787 DOI: 10.1097/Jto.0B013E31824C943F  1
2012 Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. The Journal of Thoracic and Cardiovascular Surgery. 144: 33-8. PMID 22710039 DOI: 10.1016/J.Jtcvs.2012.05.060  1
2012 Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. The Journal of Thoracic and Cardiovascular Surgery. 144: 25-32. PMID 22710038 DOI: 10.1016/J.Jtcvs.2012.05.059  1
2012 Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, Salgia R, Wang YC. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. Bmc Cancer. 12: 235. PMID 22691236 DOI: 10.1186/1471-2407-12-235  1
2012 Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes, Chromosomes & Cancer. 51: 841-51. PMID 22585712 DOI: 10.1002/Gcc.21968  1
2012 West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. Plos One. 7: e31906. PMID 22363766 DOI: 10.1371/Journal.Pone.0031906  1
2012 Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 116: 857-67. PMID 22343475 DOI: 10.1097/Aln.0B013E31824Babe2  1
2012 Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS. A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer British Journal of Cancer. 106: 839-845. PMID 22333598 DOI: 10.1038/Bjc.2012.21  1
2012 Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2175-86. PMID 22321727 DOI: 10.1096/Fj.11-196543  1
2012 Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 376-81. PMID 22198429 DOI: 10.1097/Jto.0B013E31824166A5  1
2012 Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 31: 15-24. PMID 22123719 DOI: 10.1097/Pgp.0B013E318220Ba16  1
2012 Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clinical Lung Cancer. 13: 123-8. PMID 22100149 DOI: 10.1016/J.Cllc.2011.10.001  1
2012 Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 39: 27-38. PMID 21946983 DOI: 10.1007/s00259-011-1934-6  1
2012 Lennnon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Abstract 2232: Overexpression of the mu opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth and metastasis Cancer Research. 72: 2232-2232. DOI: 10.1158/1538-7445.Am2012-2232  1
2012 Hasina R, Mutreja K, Kawada I, Kanteti R, Arif Q, Liu R, Li X, Zhou Y, Hyjek E, Lingen MW, Mueller J, Waxman I, Villaflor V, Ferguson M, Vokes EE, ... ... Salgia R, et al. Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer Cancer Research. 72: 1861-1861. DOI: 10.1158/1538-7445.Am2012-1861  1
2012 Salgia R, Nallasura, Pang H, Rolle C, Richards W, Hodgson L, Arif Q, Husain A, Kratzke R, Vokes E. An Interim Report Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens Journal of Thoracic Oncology. DOI: 10.1097/Jto.0B013E318269Fc07  1
2012 Scagliotti GV, Kim D-, Shaw AT, Ou S-I, Riely GJ, Gettinger SN, Besse B, Thomas M, Salgia R, Wilner K, Bartlett CH, Polli A, Gandara DR. A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32007-X  1
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7507. PMID 28023300 DOI: 10.1200/Jco.2011.29.15_Suppl.7507  1
2011 Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2501. PMID 28022383 DOI: 10.1200/Jco.2011.29.15_Suppl.2501  1
2011 Lennerz JK, Kwak EL, Michael M, Fox SB, Ackerman A, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang Y, Clark JW, Solomon BJ, Iafrate AJ. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4130. PMID 28021188 DOI: 10.1200/Jco.2011.29.15_Suppl.4130  1
2011 Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs of the Future. 36: 91-99. PMID 26412935 DOI: 10.1358/Dof.2011.036.02.1584112  1
2011 Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discovery. 1: 573-9. PMID 22389872 DOI: 10.1158/2159-8290.Cd-11-0175  1
2011 Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 30: 341-54. PMID 22181983 DOI: 10.1615/Jenvironpatholtoxicoloncol.V30.I4.70  1
2011 Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opinion On Biological Therapy. 11: 1655-62. PMID 22047509 DOI: 10.1517/14712598.2011.626762  1
2011 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/Jco.2011.35.4928  1
2011 Sadiq AA, Geynisman DM, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: S1810-1. PMID 22005540 DOI: 10.1097/01.Jto.0000407568.45147.43  0.01
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 12: 1004-12. PMID 21933749 DOI: 10.1016/S1470-2045(11)70232-7  1
2011 Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1741-5. PMID 21716143 DOI: 10.1097/Jto.0B013E318225924C  1
2011 Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5257-67. PMID 21712447 DOI: 10.1158/1078-0432.Ccr-11-0379  1
2011 Zhao J, He D, Berdyshev E, Zhong M, Salgia R, Morris AJ, Smyth SS, Natarajan V, Zhao Y. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. The Biochemical Journal. 439: 45-55. PMID 21696367 DOI: 10.1042/Bj20110274  1
2011 Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 446-50. PMID 21676484 DOI: 10.1016/J.Lungcan.2011.05.003  1
2011 Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 942-6. PMID 21623265 DOI: 10.1097/Jto.0B013E31821528D3  1
2011 Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 117: 5344-50. PMID 21607942 DOI: 10.1002/Cncr.26153  1
2011 Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, ... ... Salgia R, et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. Journal of Clinical Bioinformatics. 1: 1-11. PMID 21603121 DOI: 10.1186/2043-9113-1-8  1
2011 Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1418-25. PMID 21597387 DOI: 10.1097/Jto.0B013E318220C93E  1
2011 Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, ... ... Salgia R, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology & Therapy. 12: 9-46. PMID 21543897 DOI: 10.4161/Cbt.12.1.15747  1
2011 Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Seminars in Oncology. 38: 274-83. PMID 21421117 DOI: 10.1053/J.Seminoncol.2011.01.012  1
2011 Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. Journal of Carcinogenesis. 10: 4. PMID 21383961 DOI: 10.4103/1477-3163.77274  1
2011 Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3112-22. PMID 21364031 DOI: 10.1158/1078-0432.Ccr-10-1264  1
2011 Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Advances in Therapy. 28: 173-94. PMID 21337123 DOI: 10.1007/S12325-010-0103-9  1
2011 Liu W, He L, Ramírez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Research. 71: 2423-7. PMID 21292812 DOI: 10.1158/0008-5472.Can-10-2689  1
2011 Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 786-9. PMID 21289521 DOI: 10.1097/Jto.0B013E31820A443F  1
2011 Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthesia and Analgesia. 112: 558-67. PMID 21156980 DOI: 10.1213/Ane.0B013E31820568Af  1
2011 Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 25: 281-9. PMID 21072051 DOI: 10.1038/Leu.2010.263  1
2011 Mackinnon AC, Tretiakova M, Henderson L, Mehta RG, Yan BC, Joseph L, Krausz T, Husain AN, Reid ME, Salgia R. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. Journal of Clinical Pathology. 64: 16-24. PMID 21045234 DOI: 10.1136/Jcp.2010.075853  1
2011 Catenacci DVT, Henderson L, Cervantes G, El-Hashani E, Karrison T, Grushko T, Olopade F, Tretiakova M, Kindler HL, Salgia R. Abstract LB-124: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma Cellular and Molecular Biology. 71. DOI: 10.1158/1538-7445.Am2011-Lb-124  1
2011 Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson E, Jassem J, Rzyman W, Chen P, Das S, Lingen M, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, et al. Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer Cancer Research. 71: 5136-5136. DOI: 10.1158/1538-7445.Am2011-5136  1
2011 Moss RA, Bothos JG, Patel PH, Peterson AC, Eppler S, Bai S, Nijem I, Desnoyers L, Kaur S, Zha J, Yu W, Simpson J, Ratain MJ, Tan AR, Stein MN, ... ... Salgia R, et al. Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies Cancer Research. 71: 4717-4717. DOI: 10.1158/1538-7445.Am2011-4717  1
2011 Hasina R, Kawada I, Lennon F, Kanade G, Nallasura V, Kanteti R, Husain AN, Vigneswaran W, Kindler H, Vokes EE, Singleton P, Salgia R. Abstract 2341: Functional analysis of paxillin mutations identified in lung cancer and malignant mesothelioma: Implications for cell migration/motility Cancer Research. 71: 2341-2341. DOI: 10.1158/1538-7445.Am2011-2341  1
2011 Hasina R, Kanade G, Yala S, Mollberg N, Muller J, Surati M, Kanteti R, Husain A, Posner M, Waxman I, Vigneswaran W, Ferguson M, Villaflor V, Vokes EE, Gill P, ... Salgia R, et al. Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition Cancer Research. 71: 1625-1625. DOI: 10.1158/1538-7445.Am2011-1625  1
2010 Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3. PMID 27937460 DOI: 10.1200/Jco.2010.28.18_Suppl.3  1
2010 Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 2044-6. PMID 21102269 DOI: 10.1097/Jto.0B013E318200F9Ff  1
2010 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... ... Salgia R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/Nejmoa1006448  1
2010 Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. The Journal of Biological Chemistry. 285: 32596-605. PMID 20622007 DOI: 10.1074/Jbc.M110.106161  1
2010 Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2598-603. PMID 20385980 DOI: 10.1200/Jco.2009.26.7682  0.01
2010 Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. The Journal of Biological Chemistry. 285: 18575-85. PMID 20360610 DOI: 10.1074/Jbc.M109.075085  1
2010 Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. Journal of Angiogenesis Research. 2: 5. PMID 20298531 DOI: 10.1186/2040-2384-2-5  1
2010 Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, ... ... Salgia R, et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. Plos One. 5: e8972. PMID 20126411 DOI: 10.1371/Journal.Pone.0008972  1
2010 Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre Alimentary Pharmacology and Therapeutics. 31: 625-633. PMID 20003093 DOI: 10.1111/J.1365-2036.2009.04218.X  1
2010 Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A. Differential serum level of specific haptoglobin isoforms in small cell lung cancer Current Proteomics. 7: 49-56. DOI: 10.2174/157016410790979635  1
2010 Salgia R, Peterson AC, Bothos J, Eppler S, Yu W, Hegde P, Yauch B, Zha J, Ratain MJ, Geary D, Wesolowsky E, LaRosiliere M, Patel P, Moss R. Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors Cancer Research. 70: 2774-2774. DOI: 10.1158/1538-7445.Am10-2774  1
2010 El-Dinali M, Braegelmann J, Salgia R, Seiwert T. Abstract 2223: Screening for oncoviruses using next-generation sequencing Cancer Research. 70: 2223-2223. DOI: 10.1158/1538-7445.Am10-2223  1
2010 Cerri E, Kashyap S, Chen PX, Das S, Cipriani N, Kanteti R, Husain A, Salgia R, Innocenti F. Abstract 2176: Vascular endothelial growth factor receptor-2 (VEGFR-2) gene variations in bronchioloalveolar cell carcinoma (BAC) Cancer Research. 70: 2176-2176. DOI: 10.1158/1538-7445.Am10-2176  1
2009 Tan E, Salgia R, Besse B, Goss G, Gandara DR, Hanna N, Steinberg J, Steinberg J, Qian J, Carlson DM, Soo R. ABT-869 in non-small cell lung cancer (NSCLC): Interim results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8074. PMID 27962648 DOI: 10.1200/Jco.2009.27.15_Suppl.8074  1
2009 Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R. Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19006. PMID 27962520 DOI: 10.1200/Jco.2009.27.15_Suppl.E19006  1
2009 Chiappori A, Schreeder MT, Moezi MM, Stephenson J, Blakely JL, Salgia R, Chu QS, Malik SM, Modiano MM, Berger MS. A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3576. PMID 27961715 DOI: 10.1200/Jco.2009.27.15_Suppl.3576  1
2009 Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. Journal of Carcinogenesis. 8: 15. PMID 19955662 DOI: 10.4103/1477-3163.57857  1
2009 Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Research. 69: 7538-47. PMID 19738072 DOI: 10.1158/0008-5472.Can-08-4626  0.01
2009 Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, ... ... Salgia R, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5714-23. PMID 19723643 DOI: 10.1158/1078-0432.Ccr-09-0070  1
2009 Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. The Journal of Biological Chemistry. 284: 27524-32. PMID 19651775 DOI: 10.1074/Jbc.M109.047209  1
2009 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 30: 37-47. PMID 19392863 DOI: 10.1111/J.1365-2036.2009.04014.X  1
2009 Kim ES, Salgia R. MET pathway as a therapeutic target. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 444-7. PMID 19333071 DOI: 10.1097/Jto.0B013E31819D6F91  0.01
2009 Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, ... Salgia R, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Research. 69: 3021-31. PMID 19318576 DOI: 10.1158/0008-5472.Can-08-2881  1
2009 Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 301-14. PMID 19139719 DOI: 10.1038/Labinvest.2008.168  1
2009 Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, ... ... Salgia R, et al. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 28: 518-33. PMID 19015641 DOI: 10.1038/Onc.2008.411  1
2009 Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. Bju International. 103: 171-7. PMID 18990162 DOI: 10.1111/J.1464-410X.2008.08009.X  1
2009 Lennon FE, Mambetsariev N, Garcia JGN, Salgia R, Moss J, Singleton PA. Abstract C79: Methylnaltrexone inhibits EGF‐ and IGF‐induced human bronchioloalveolar carcinoma proliferation and migration Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C79  1
2009 Mathew B, Lennon FE, Siegler J, Gerhold L, Mambetsariev N, Moreno‐Vinasco L, Garcia JGN, Salgia R, Moss J, Singleton P. Abstract C78: The mu opioid receptor regulates Lewis lung carcinoma tumor growth and metastasis Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C78  1
2009 Dinali ME, Braegelmann J, Stricker T, Brown C, Salgia R, Vokes E, White K, Seiwert T. Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A207  1
2009 Zoergiebel J, Kundu A, Braegelmann J, Shen W, Dinali ME, Salgia R, Seiwert T. Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A165  1
2008 Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3522. PMID 27949731 DOI: 10.1200/Jco.2008.26.15_Suppl.3522  1
2008 Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, Rowland KM, Salgia R, Aggarwal N, Gadgeel SM. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8053. PMID 27948945 DOI: 10.1200/Jco.2008.26.15_Suppl.8053  1
2008 Faoro L, Hutto JY, Salgia R, El-Zayaty SA, Ferguson MK, Cheney RT, Reid ME, Armato SG, Krausz T, Husain AN. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Archives of Pathology & Laboratory Medicine. 132: 1882-8. PMID 19061284 DOI: 10.1043/1543-2165-132.12.1882  1
2008 Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anti-Cancer Drugs. 19: 841-8. PMID 18765998 DOI: 10.1097/Cad.0B013E32830Ce506  1
2008 Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1003-11. PMID 18758303 DOI: 10.1097/Jto.0B013E31818396A4  1
2008 Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer. 47: 1025-37. PMID 18709663 DOI: 10.1002/Gcc.20604  1
2008 Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 113: 808-14. PMID 18543326 DOI: 10.1002/Cncr.23617  1
2008 Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 1104-10. PMID 18483332 DOI: 10.1158/1055-9965.Epi-07-2713  1
2008 Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology. 110: 49-55. PMID 18423560 DOI: 10.1016/J.Ygyno.2008.02.009  1
2008 Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology & Therapy. 7: 856-63. PMID 18340114 DOI: 10.4161/Cbt.7.6.5842  1
2008 Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 870-6. PMID 18281659 DOI: 10.1200/Jco.2007.14.3461  1
2008 Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, ... ... Salgia R, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Research. 68: 132-42. PMID 18172305 DOI: 10.1158/0008-5472.Can-07-1998  1
2008 Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 18: 976-84. PMID 18021219 DOI: 10.1111/J.1525-1438.2007.01135.X  1
2008 Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology. 61: 549-58. PMID 17522864 DOI: 10.1007/S00280-007-0500-1  1
2007 Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anti-Cancer Agents in Medicinal Chemistry. 7: 633-42. PMID 18045058 DOI: 10.2174/187152007784111322  1
2007 Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Garcia JG. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. The Journal of Biological Chemistry. 282: 30643-57. PMID 17702746 DOI: 10.1074/Jbc.M702573200  1
2007 Zhao Y, He D, Stern R, Usatyuk PV, Spannhake EW, Salgia R, Natarajan V. Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cellular Signalling. 19: 2329-38. PMID 17689924 DOI: 10.1016/J.Cellsig.2007.07.005  1
2007 Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. British Journal of Cancer. 97: 368-77. PMID 17667909 DOI: 10.1038/Sj.Bjc.6603884  1
2007 Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. American Journal of Clinical Oncology. 30: 258-63. PMID 17551302 DOI: 10.1097/01.Coc.0000258109.83083.78  1
2007 Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrometry Reviews. 26: 451-66. PMID 17407130 DOI: 10.1002/Mas.20125  1
2007 Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Current Molecular Medicine. 7: 77-84. PMID 17311534 DOI: 10.2174/156652407779940486  1
2007 Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research. 67: 1670-9. PMID 17308108 DOI: 10.1158/0008-5472.Can-06-1147  1
2007 Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 515-22. PMID 17255273 DOI: 10.1158/1078-0432.Ccr-06-1058  1
2006 Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas Clinical Cancer Research. 12: 7261-7270. PMID 17189397 DOI: 10.1158/1078-0432.Ccr-06-0874  1
2006 Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology (Carlton, Vic.). 11: 687-92. PMID 17052295 DOI: 10.1111/J.1440-1843.2006.00887.X  1
2006 Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, Salgia R. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 54: 243-5. PMID 16949700 DOI: 10.1016/J.Lungcan.2006.07.017  0.01
2006 Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nature Clinical Practice. Oncology. 3: 50-7; quiz 1 p follo. PMID 16407879 DOI: 10.1038/Ncponc0400  1
2006 Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, ... ... Salgia R, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Research. 66: 352-61. PMID 16397249 DOI: 10.1158/0008-5472.Can-04-4567  1
2005 Rudin CM, Salgia R, Wang XF, Green MR, Vokes EE. CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7168. PMID 27944986 DOI: 10.1200/Jco.2005.23.16_Suppl.7168  1
2005 Cunningham C, Richards D, Salgia R, Leonard R, Raju R, Arseneau J, Packer S, Gregoire L, Haltom E, Uprichard MJ. Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7120. PMID 27944217 DOI: 10.1200/Jco.2005.23.16_Suppl.7120  0.01
2005 Jacobs M, Weber R, Hainsworth J, Schwartzberg L, Strauss J, Tatsuta N, Du Z, McLeod M, Dahl T, Salgia R. A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naïve advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7106. PMID 27944185 DOI: 10.1200/Jco.2005.23.16_Suppl.7106  0.01
2005 Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Research. 65: 5301-9. PMID 15958577 DOI: 10.1158/0008-5472.Can-04-3270  1
2005 Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion On Therapeutic Targets. 9: 533-59. PMID 15948672 DOI: 10.1517/14728222.9.3.533  1
2005 Hahn O, Salgia R. Novel therapies in lung cancer. Hematology/Oncology Clinics of North America. 19: 343-67, vii. PMID 15833410 DOI: 10.1016/J.Hoc.2005.02.005  1
2005 Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2312-9. PMID 15788682 DOI: 10.1158/1078-0432.Ccr-04-1708  1
2005 Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Research. 65: 1479-88. PMID 15735036 DOI: 10.1158/0008-5472.Can-04-2650  1
2005 Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 105: 1717-23. PMID 15486067 DOI: 10.1182/Blood-2004-03-0849  1
2004 Ma PC, Tretiakova MS, Jagadeeswaran R, Jagadeesh S, Nallasura V, Kindler HL, Lingen M, Vokes EE, Husain A, Salgia R. Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9539. PMID 28016812 DOI: 10.1200/Jco.2004.22.14_Suppl.9539  1
2004 Salgia R, Berkenblit A, Dezube B, Dahl TA, Koya K. STA-4783, a novel HSP inducer, enhances paclitaxel activity-Preclinical to clinical modeling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3124. PMID 28014871 DOI: 10.1200/Jco.2004.22.14_Suppl.3124  0.01
2004 Ma PC, Salgia R. Novel targets for therapeutic agents in small cell lung cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 2: 165-72. PMID 19777705 DOI: 10.6004/Jnccn.2004.0014  1
2004 Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine & Growth Factor Reviews. 15: 419-33. PMID 15561600 DOI: 10.1016/J.Cytogfr.2004.09.002  1
2004 Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 23: 237-51. PMID 15511212 DOI: 10.1615/Jenvpathtoxoncol.V23.I4.10  1
2004 Mukhopadhyay NK, Gilchrist D, Gordon GJ, Chen CJ, Bueno R, Lu ML, Salgia R, Sugarbaker DJ, Jaklitsch MT. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. The Annals of Thoracic Surgery. 78: 450-7. PMID 15276495 DOI: 10.1016/J.Athoracsur.2004.01.042  1
2004 Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treatment and Research. 119: 121-38. PMID 15164876 DOI: 10.1007/1-4020-7847-1_7  1
2003 Lee D, Belani CP, Salgia R. Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. Clinical Lung Cancer. 5: 86-89. PMID 14596690 DOI: 10.1016/S1525-7304(11)70325-4  0.01
2003 Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 22: 147-65. PMID 14529091 DOI: 10.1615/Jenvpathtoxoncol.V22.I3.10  1
2003 Kijima T, Maulik G, Ma PC, Madhiwala P, Schaefer E, Salgia R. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. Journal of Cellular and Molecular Medicine. 7: 157-64. PMID 12927054 DOI: 10.1111/J.1582-4934.2003.Tb00214.X  1
2003 Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Reviews. 22: 309-25. PMID 12884908 DOI: 10.1023/A:1023768811842  1
2003 Brown JR, Wieczorek TJ, Shaffer K, Salgia R. Small-cell cancers, and an unusual reaction to chemotherapy: Case 1. Extrapulmonary small-cell carcinoma arising in the prostate Journal of Clinical Oncology. 21: 2437-2439. PMID 12805344 DOI: 10.1200/Jco.2003.081.03  1
2003 Trie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Case 4. Primary lymphoepithelioma-like carcinoma of the lung Journal of Clinical Oncology. 21: 2220-2222. PMID 12775751 DOI: 10.1200/Jco.2003.09.088  1
2003 Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer Oncologist. 8: 69-75. PMID 12604733 DOI: 10.1634/Theoncologist.8-1-69  1
2003 Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 624-30. PMID 12586798 DOI: 10.1200/Jco.2003.03.091  1
2002 Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. Journal of Cellular and Molecular Medicine. 6: 539-53. PMID 12611639 DOI: 10.1111/J.1582-4934.2002.Tb00453.X  1
2002 Liu S, Kiosses WB, Rose DM, Slepak M, Salgia R, Griffin JD, Turner CE, Schwartz MA, Ginsberg MH. A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. The Journal of Biological Chemistry. 277: 20887-94. PMID 11919182 DOI: 10.1074/Jbc.M110928200  1
2002 Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells Oncogene. 21: 1423-1433. PMID 11857085 DOI: 10.1038/Sj.Onc.1205202  1
2002 Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine & Growth Factor Reviews. 13: 41-59. PMID 11750879 DOI: 10.1016/S1359-6101(01)00029-6  1
2000 Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19: 3521-8. PMID 10918610 DOI: 10.1038/Sj.Onc.1203698  1
2000 Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells Journal of Biological Chemistry. 275: 24273-24278. PMID 10833515 DOI: 10.1074/Jbc.M002094200  1
1999 Thomas JW, Cooley MA, Broome JM, Salgia R, Griffin JD, Lombardo CR, Schaller MD. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin Journal of Biological Chemistry. 274: 36684-36692. PMID 10593973 DOI: 10.1074/Jbc.274.51.36684  1
1999 Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 94: 4233-46. PMID 10590068  1
1999 Sun Y, Zhang J, Kraeft SK, Auclair D, Chang MS, Liu Y, Sutherland R, Salgia R, Griffin JD, Ferland LH, Chen LB. Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. The Journal of Biological Chemistry. 274: 33522-30. PMID 10559237 DOI: 10.1074/Jbc.274.47.33522  1
1999 Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility Oncogene. 18: 67-77. PMID 9926921 DOI: 10.1038/Sj.Onc.1202273  1
1999 Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, Andrian UHv, Chen LB, Gutierrez-Ramos J, Pendergast A, et al. The BCR/ABL Oncogene Alters the Chemotactic Response to Stromal-Derived Factor-1 Blood. 94: 4233-4246. DOI: 10.1182/Blood.V94.12.4233.424K37_4233_4246  1
1997 Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, Salgia R, Golemis EA, Freedman AS. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leukemia & Lymphoma. 28: 65-72. PMID 9498705 DOI: 10.3109/10428199709058332  0.01
1997 Manié SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. The Journal of Biological Chemistry. 272: 4230-6. PMID 9020138 DOI: 10.1074/Jbc.272.7.4230  1
1995 Chakravarty A, Salgia R, Mason E, Rajendran R, Muthuswamy P. Pneumonia and infraorbital abscess in a 29-year-old diabetic pregnant woman. Chest. 107: 1752-4. PMID 7781379 DOI: 10.1378/chest.107.6.1752  0.01
1995 Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. The Journal of Biological Chemistry. 270: 5039-47. PMID 7534286 DOI: 10.1074/Jbc.270.10.5039  1
1995 Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. The Journal of Biological Chemistry. 270: 29145-50. PMID 7493940 DOI: 10.1074/Jbc.270.49.29145  1
1994 Salgia R, Demetri GD, Kaplan WD. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer: A case report Cancer. 74: 1887-1890. PMID 7521785 DOI: 10.1002/1097-0142(19941001)74:7<1887::AID-CNCR2820740710>3.0.CO;2-6  1
1993 Salgia R, Becker JH, Sayeed MM. Altered membrane fluidity in rat hepatocytes during endotoxic shock Molecular and Cellular Biochemistry. 121: 143-148. PMID 8316231 DOI: 10.1007/Bf00925973  1
Show low-probability matches.